These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1409 related items for PubMed ID: 25259745

  • 1. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M, ALLHAT Collaborative Research Group.
    Hypertension; 2014 Nov; 64(5):1012-21. PubMed ID: 25259745
    [Abstract] [Full Text] [Related]

  • 2. Prevalence of Apparent Therapy-Resistant Hypertension and Its Effect on Outcome in Patients With Chronic Kidney Disease.
    de Beus E, Bots ML, van Zuilen AD, Wetzels JF, Blankestijn PJ, MASTERPLAN Study Group.
    Hypertension; 2015 Nov; 66(5):998-1005. PubMed ID: 26351024
    [Abstract] [Full Text] [Related]

  • 3. Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study.
    Thomas G, Xie D, Chen HY, Anderson AH, Appel LJ, Bodana S, Brecklin CS, Drawz P, Flack JM, Miller ER, Steigerwalt SP, Townsend RR, Weir MR, Wright JT, Rahman M, CRIC Study Investigators.
    Hypertension; 2016 Feb; 67(2):387-96. PubMed ID: 26711738
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular Health and Transition From Controlled Blood Pressure to Apparent Treatment Resistant Hypertension: The Jackson Heart Study and the REGARDS Study.
    Akinyelure OP, Sakhuja S, Colvin CL, Clark D, Jaeger BC, Hardy ST, Howard G, Cohen LP, Irvin MR, Tanner R, Carey RM, Muntner P.
    Hypertension; 2020 Dec; 76(6):1953-1961. PubMed ID: 33131312
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality.
    Irvin MR, Booth JN, Shimbo D, Lackland DT, Oparil S, Howard G, Safford MM, Muntner P, Calhoun DA.
    J Am Soc Hypertens; 2014 Jun; 8(6):405-13. PubMed ID: 24952653
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J, ALLHAT Collaborative Research Group.
    Arch Intern Med; 2006 Nov 13; 166(20):2191-201. PubMed ID: 17101936
    [Abstract] [Full Text] [Related]

  • 9. The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Kronish IM, Lynch AI, Oparil S, Whittle J, Davis BR, Simpson LM, Krousel-Wood M, Cushman WC, Chang TI, Muntner P.
    Hypertension; 2016 Jul 13; 68(1):39-45. PubMed ID: 27217410
    [Abstract] [Full Text] [Related]

  • 10. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S, Bakir SE.
    Drugs; 2000 Jul 13; 59 Spec No 2():25-37. PubMed ID: 11002856
    [Abstract] [Full Text] [Related]

  • 11. Prediction of cardiovascular and renal risk among patients with apparent treatment-resistant hypertension in the United States using machine learning methods.
    Bakris G, Lin PP, Xu C, Chen C, Ashton V, Singhal M.
    J Clin Hypertens (Greenwich); 2024 May 13; 26(5):500-513. PubMed ID: 38523465
    [Abstract] [Full Text] [Related]

  • 12. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.
    Bangalore S, Davis BR, Cushman WC, Pressel SL, Muntner PM, Calhoun DA, Kostis JB, Whelton PK, Probstfield JL, Rahman M, Black HR, ALLHAT Collaborative Research Group.
    Am J Med; 2017 Apr 13; 130(4):439-448.e9. PubMed ID: 27984005
    [Abstract] [Full Text] [Related]

  • 13. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
    Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard A, ALLHAT Collaborative Research Group.
    J Am Coll Cardiol; 2009 Nov 24; 54(22):2023-31. PubMed ID: 19926008
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.
    Hypertension; 2003 Sep 24; 42(3):239-46. PubMed ID: 12925554
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Clinical study of the month. Which initial antihypertensive? Results from the ALLHAT trial].
    Scheen AJ, Krzesinski JM.
    Rev Med Liege; 2003 Jan 24; 58(1):47-52. PubMed ID: 12647599
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.